跳至主要内容
临床试验/NCT06256497
NCT06256497暂停不适用

Revita DMR Post Market Pilot Clinical Registry

Fractyl Health Inc.1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年6月27日最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
入组人数
100
试验地点
1
主要终点
Clinical effectiveness

研究概览

简要总结

The Revita DMR Post Market Pilot Clinical Registry is a post-market, prospective, observational, noninterventional clinical registry in patients with T2D in Germany undergoing the Revita Procedure with the CE marked Revita System (Fractyl Health, Lexington, MA, USA) in accordance with its intended purposes. Patient's participation in this study has no impact on his or her indication or opportunity to receive therapy. Patients are to be treated in compliance with the current Revita System's IFU of the CE marked Revita System as well as according to medical society guidelines and physician discretion.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed and dated informed consent in accordance with GCP and local legislation
  • Adults (≥18 years) with the diagnosis of T2D
  • BMI of <=45 kg/m2 at the time of presentation/screening
  • T2D mellitus inadequately controlled on therapy (HbA1c ≥7.0 and ≤10.0% [53-86 mmol/mol] at the time of initial presentation for screening and with the need for therapy escalation [dose increase of existing therapy or additional prescription of insulin and/or OADs or change of therapy regimen]) to achieve the therapeutic HbA1c target defined by the physician
  • Treatment with oral and/or injectable glucose lowering medications and/or long-acting insulin therapy

排除标准

  • 未提供

结局指标

主要结局

Clinical effectiveness

时间窗: Baseline, 1, 3-, 6-, 12-, and 24-months post-procedure.

Changes in antidiabetic medication dosages

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验